Market Snapshot
S&P Futures
4,132.25
Dow Futures
32,794
Nasdaq Futures
13,101.5
Finch Therapeutics Group, Inc. (FNCH) stock rallied over 6.64% intraday to trade at $2.41 a share on NASDAQ. The stock opened with a gain of 5.70% at $2.38 and touched an intraday high of $2.55, rising 6.64% against the last close of $2.26. The stock went to a low of $2.23 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-08-08 | $2.38 | $2.55 | $2.23 | $2.41 | 47,433 |
2022-08-05 | $2.28 | $2.37 | $2.12 | $2.26 | 68,200 |
2022-08-04 | $2 | $2.38 | $2 | $2.22 | 35,400 |
2022-08-03 | $1.88 | $2.103 | $1.82 | $2.03 | 41,100 |
2022-08-02 | $1.78 | $2.09 | $1.74 | $1.9 | 92,000 |
2022-08-01 | $1.89 | $1.95 | $1.85 | $1.85 | 20,900 |
2022-07-29 | $2.04 | $2.04 | $1.91 | $1.95 | 29,200 |
2022-07-28 | $2.01 | $2.09 | $1.95 | $1.95 | 22,600 |
2022-07-27 | $2.01 | $2.06 | $1.92 | $2.02 | 18,700 |
2022-07-26 | $2.08 | $2.08 | $1.85 | $1.99 | 42,500 |
Employees-
Beta-
Sales or Revenue15.33 Million
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Finch Therapeutics Group, Inc. (NASDAQ: FNCH) stock price is $2.41 as of the last check on Monday, August 8. During the trading session, FNCH stock reached the peak price of $2.55 while $2.23 was the lowest point it dropped to.
The NASDAQ listed FNCH is part of Biotechnology industry that operates in the broader Health Care sector. Finch Therapeutics Group, Inc. , a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.
Dr. Mark Burnham Smith Ph.D.
CEO & Director
Mr. Marc B. Blaustein C.F.A., CFA, MPP
Chief Operating Officer
Mr. Joseph D. Vittiglio Esq., J.D.
Chief Bus. & Legal Officer and Corp. Sec.
Mr. Gregory D. Perry
Chief Financial Officer
FNCH stock traded closed the last session at $2.41, which is $0.15000000000000036 or 6.637168141592936% lower than its previous close of $2.26. FNCH's current trading price is 40.8% lower than its 52-week high of $17.39 where as its distance from 52-week low of 1.71% is -86.14%.
Number of FNCH employees currently stands at -. FNCH operates from 200 Inner Belt Road, Suite 400, Somerville, MA 02143, United States.
Official Webiste of $FNCH is: https://www.finchtherapeutics.com
FNCH could be contacted at FNCH operates from 200 Inner Belt Road, Suite 400, Somerville, MA 02143, United States, or at phone #617 229 6499 and can also be accessed through its website.
FNCH stock volume for the day was 47,434 shares while in the previous session number of FNCH shares traded was 47,433 . The average number of FNCH shares traded daily for last 3 months was 121.63 Thousands.
The percentage change in FNCH stock occurred in the recent session was 6.637168141592936% while the dollar amount for the price change in FNCH stock was $0.15000000000000036.
In the recent session, the day high for FNCH stock was $2.55 while the low for FNCH stock touched on the day was $2.23.
The market value of FNCH currently stands at 112.62 Million with its latest stock price at $2.41 and 47.53 Million of its shares outstanding.